Subunit influenza vaccine
Phase 1Vaccine
NovartisSubunit influenza vaccine is one of 23 biologic programs targeting Influenza. It is currently in Phase 1.
1
Indications
3
Total Trials
1
Active Trials
22
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1053 competitors in Influenza
#DrugCompanyPhaseTrials
1Fluzone
SanofiPreclinical
Fluzone
GSKPreclinical
Trexall
Alnylam PharmaceuticalsPreclinical
Crestor
AstraZenecaPreclinical
Avigan
AAppili Therapeutics Inc.
Preclinical
Quadrivalent Influenza Vaccine
SanofiPreclinical
COMIRNATY
PfizerPreclinical
Focetria
CChiltern Pesquisa Clinica Ltda
Preclinical
Subunit influenza vaccine
NovartisPhase 1
Influenza A/H5N1
NNational Institute of Allergy and Infectious Diseases (NIAID)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Subunit influenza vaccine. EMBL-EBI & Wellcome Sanger Institute.
- [4]